Last reviewed · How we verify

MRG004A plus best supportive care — Competitive Intelligence Brief

MRG004A plus best supportive care (MRG004A plus best supportive care) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody. Area: Oncology.

phase 3 Bispecific antibody Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MRG004A plus best supportive care (MRG004A plus best supportive care) — Shanghai Miracogen Inc.. MRG004A is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MRG004A plus best supportive care TARGET MRG004A plus best supportive care Shanghai Miracogen Inc. phase 3 Bispecific antibody
Elrexfio elranatamab Pfizer marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells 2023-01-01
Elrexfio Elranatamab Pfizer marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells 2023-01-01
Elrantamab elrantamab Pfizer marketed Bispecific Antibody BCMA (B-cell maturation antigen)
BAT1706 BAT1706 Bio-Thera Solutions phase 3 Bispecific antibody; PD-1/TGF-β inhibitor PD-1 and TGF-β
M701 M701 Wuhan YZY Biopharma Co., Ltd. phase 3 Bispecific antibody
HZT-501 HZT-501 Amgen phase 3 Bispecific antibody

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody class)

  1. Shanghai Miracogen Inc. · 3 drugs in this class
  2. Atom Therapeutics Co., Ltd · 2 drugs in this class
  3. Pfizer · 2 drugs in this class
  4. Allergan · 1 drug in this class
  5. AstraZeneca · 1 drug in this class
  6. BioNTech SE · 1 drug in this class
  7. DualityBio Inc. · 1 drug in this class
  8. Coherus Oncology, Inc. · 1 drug in this class
  9. Genmab · 1 drug in this class
  10. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MRG004A plus best supportive care — Competitive Intelligence Brief. https://druglandscape.com/ci/mrg004a-plus-best-supportive-care. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: